Clements JN - Search Results

1

Liraglutide: an injectable option for the management of obesity.

Clements JN, Shealy KM. Clements JN, et al. Ann Pharmacother. 2015 Aug;49(8):938-44. doi: 10.1177/1060028015586806. Epub 2015 May 18. Ann Pharmacother. 2015. PMID: 25986009 Review.

2

Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.

Clements JN, Whitley HP, D'Souza JJ, Gross B, Hess R, Reece S, Gentry C, Shealy K. Clements JN, et al. Curr Med Res Opin. 2015;31(9):1733-41. doi: 10.1185/03007995.2015.1069739. Epub 2015 Aug 20. Curr Med Res Opin. 2015. PMID: 26285788 Review.

3

Team-Based Approach to Obesity Management.

Shealy K, Wagner S, Clements J, Pugh A. Shealy K, et al. J S C Med Assoc. 2014 Sep-Oct;110(3):98-100. J S C Med Assoc. 2014. PMID: 27124994 No abstract available.

4

Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.

Clements JN, Threatt T, Ward E, Shealy KM. Clements JN, et al. Clin Pharmacokinet. 2017 May;56(5):449-458. doi: 10.1007/s40262-016-0464-6. Clin Pharmacokinet. 2017. PMID: 27699623 Review.

5

Liraglutide, GLP-1 receptor agonist, for chronic weight loss.

Moore KG, Shealy K, Clements JN. Moore KG, et al. Among authors: clements jn. Expert Rev Endocrinol Metab. 2016 Sep;11(5):373-378. doi: 10.1080/17446651.2016.1220295. Epub 2016 Aug 11. Expert Rev Endocrinol Metab. 2016. PMID: 30058906

6

Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes.

Clements J, Moore K, Shealy K. Clements J, et al. Expert Rev Endocrinol Metab. 2015 Nov;10(6):581-590. doi: 10.1586/17446651.2015.1098532. Epub 2015 Oct 13. Expert Rev Endocrinol Metab. 2015. PMID: 30289034

7

Clinical review of subcutaneous semaglutide for obesity.

Phillips A, Clements JN. Phillips A, et al. Among authors: clements jn. J Clin Pharm Ther. 2022 Feb;47(2):184-193. doi: 10.1111/jcpt.13574. Epub 2021 Dec 28. J Clin Pharm Ther. 2022. PMID: 34964141 Review.

8

Canagliflozin: a new option for managing diabetes.

Livingston M, Clements JN. Livingston M, et al. Among authors: clements jn. JAAPA. 2014 Sep;27(9):47-50. doi: 10.1097/01.JAA.0000453247.76333.09. JAAPA. 2014. PMID: 25148443

9

Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus.

Clements JN, Bello L. Clements JN, et al. Am J Health Syst Pharm. 2016 Mar 15;73(6):359-66. doi: 10.2146/ajhp150174. Am J Health Syst Pharm. 2016. PMID: 26953280 Review.

10

Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.

Hall S, Isaacs D, Clements JN. Hall S, et al. Among authors: clements jn. Clin Pharmacokinet. 2018 Dec;57(12):1529-1538. doi: 10.1007/s40262-018-0668-z. Clin Pharmacokinet. 2018. PMID: 29915923 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters